FDA Panel Votes to Allow Compounding of BPC-157 Peptide Despite Scant Safety Data

A Food and Drug Administration advisory committee voted on Thursday to recommend adding the peptide BPC-157 to a drug compounding list, moving the widely discussed supplement one step closer to being legally available to Americans with a prescription. The vote was 8-6 in favour, with one abstention.

What the Vote Means

The vote by the Pharmacy Compounding Advisory Committee (PCAC) is non-binding: it still requires final sign-off from the FDA itself before BPC-157 can be legally compounded and dispensed. BPC-157 is the first of seven peptides the committee is reviewing in hearings that run through Thursday and Friday.

If approved, compounding would allow licensed pharmacists to prepare custom doses of BPC-157 for individual patients with a doctor's prescription — an alternative regulatory pathway that bypasses the full, more stringent FDA drug approval process.

Little Evidence, Big Popularity

BPC-157 has attracted enormous attention online, where influencers and wellness communities have promoted it as a treatment for gut healing, tissue repair, and a range of other conditions. However, FDA staff scientists highlighted at Thursday's meeting that there is very little quality human clinical trial data to support claims of effectiveness or safety.

Most studies supporting BPC-157's potential have been conducted on rodents — results that do not always translate to humans when larger clinical trials are conducted. Committee members who voted in favour generally argued that the risks associated with compounded BPC-157 are minimal. Those who voted against expressed concern about creating a false impression of regulatory approval and about safety risks that remain unquantified.

Political Context and Conflicts of Interest

The hearings come with notable political backdrop. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly promoted the use of peptides, and HHS has faced criticism that several newly appointed members of the PCAC have financial conflicts of interest. The FDA has not yet responded to those conflict-of-interest allegations.